MARKET

VSTM

VSTM

Verastem
NASDAQ
4.685
-0.055
-1.16%
After Hours: 4.770 +0.085 +1.81% 19:56 07/11 EDT
OPEN
4.720
PREV CLOSE
4.740
HIGH
4.750
LOW
4.580
VOLUME
1.21M
TURNOVER
--
52 WEEK HIGH
9.10
52 WEEK LOW
2.100
MARKET CAP
257.44M
P/E (TTM)
-1.4699
1D
5D
1M
3M
1Y
5Y
1D
Verastem publishes RAMP 201 trial data in Journal of Clinical Oncology
TipRanks · 3d ago
Verastem's Ovarian Cancer Trial Results Published In Journal Of Clinical Oncology, Titled "Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer"; Verastem's Avutometinib Combo Shows 31% Overall Response Rate In Ovarian Cancer Trial
Benzinga · 3d ago
Verastem Oncology Secures FDA Approval for Avutometinib Plus Defactinib Combination in KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Reuters · 3d ago
VERASTEM ONCOLOGY ANNOUNCES PUBLICATION OF THE PRIMARY RESULTS FROM THE PHASE 2 RAMP 201 TRIAL OF AVUTOMETINIB IN COMBINATION WITH DEFACTINIB IN PATIENTS WITH RECURRENT LOW-GRADE SEROUS OVARIAN CANCER IN THE JOURNAL OF CLINICAL ONCOLOGY
Reuters · 3d ago
RBC Capital Sticks to Its Buy Rating for Verastem (VSTM)
TipRanks · 5d ago
GLOBAL ONCOLOGY BREAKTHROUGHS BEING FUELED BY ADVANCEMENTS IN CLINICAL TRIALS AND NEW THERAPIES
Reuters · 6d ago
Verastem Oncology Announces Stock Option Inducement Grants for New Employees Under Nasdaq Rule
Reuters · 6d ago
VERASTEM ONCOLOGY ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.